Literature DB >> 9846389

Medication compliance in patients with chronic schizophrenia: implications for the community management of mentally disordered offenders.

J C Duncan1, R Rogers.   

Abstract

The safe and effective management of mentally disordered offenders is a paramount concern in decisions for community placement. Treatment effectiveness is often vitiated by medication noncompliance. In the current study, clinical and sociodemographic correlates of treatment compliance were examined in outpatients with schizophrenia. Level of medication compliance, assessed independently by treatment staff at two outpatient settings, resulted in 40 compliant, 38 noncompliant, and 12 partially compliant patients. Key symptoms associated with medication noncompliance were anger, delusions, and hallucinations. As an initial investigation, a stepwise discriminant analysis was moderately successful at predicting medication noncompliance. The implications of these findings to mentally disordered offenders are explored.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9846389

Source DB:  PubMed          Journal:  J Forensic Sci        ISSN: 0022-1198            Impact factor:   1.832


  10 in total

1.  Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Authors:  Natalie C Edwards; Julie C Locklear; Marcia F T Rupnow; Ronald J Diamond
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Noncompliance in the use of cardiovascular medications in the Medicare Part D population.

Authors:  Steven A Blackwell; David K Baugh; Melissa A Montgomery; Gary M Ciborowski; Charles J Waldron; Gerald F Riley
Journal:  Medicare Medicaid Res Rev       Date:  2011-12-14

3.  Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition.

Authors:  M R Kraus; A Schäfer; H Csef; H Faller; H Mörk; M Scheurlen
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

4.  Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.

Authors:  Natalie C Edwards; Marcia F T Rupnow; Chris L Pashos; Marc F Botteman; Ronald J Diamond
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Recovery and serious brain disorders: the central role of families in nurturing roots and wings.

Authors:  L L Hall; R Purdy
Journal:  Community Ment Health J       Date:  2000-08

Review 6.  Defining and assessing adherence to oral antipsychotics: a review of the literature.

Authors:  Dawn I Velligan; Yui-Wing Francis Lam; David C Glahn; Jennifer A Barrett; Natalie J Maples; Larry Ereshefsky; Alexander L Miller
Journal:  Schizophr Bull       Date:  2006-05-17       Impact factor: 9.306

7.  Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.

Authors:  Karen L Rascati; Michael T Johnsrud; M Lynn Crismon; Maureen J Lage; Beth L Barber
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

8.  Person-centered care planning and service engagement: a study protocol for a randomized controlled trial.

Authors:  Victoria Stanhope; Janis Tondora; Larry Davidson; Mimi Choy-Brown; Steven C Marcus
Journal:  Trials       Date:  2015-04-22       Impact factor: 2.279

9.  Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER.

Authors:  Michael Birnbaum; Zafar Sharif
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

10.  Health Inequalities Among Elderly Type 2 Diabetes Mellitus Patients in Japan.

Authors:  Peng Jiang; Akira Babazono; Takako Fujita
Journal:  Popul Health Manag       Date:  2019-10-29       Impact factor: 2.459

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.